A1 Refereed original research article in a scientific journal

Risk factors associated with IgG seropersistence to Chlamydia trachomatis and Mycoplasma genitalium




AuthorsKoskela, Nea; Butt, Julia; Michels, Birgitta; Syrjänen, Kari; Grenman, Seija; Waterboer, Timo; Syrjänen, Stina; Louvanto, Karolina

PublisherCambridge University Press

Publication year2025

JournalEpidemiology and Infection

Journal name in sourceEpidemiology and Infection

Article numbere104

Volume153

First page 1

Last page7

ISSN0950-2688

eISSN1469-4409

DOIhttps://doi.org/10.1017/S095026882500007X

Web address https://doi.org/10.1017/S095026882500007X

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/499692946


Abstract

Sexually transmitted infections caused by Chlamydia trachomatis (Ct) and Mycoplasma genitalium (Mg) have significant implications both at the individual and societal levels. Our study evaluated various co-factors associations with persistent serum IgG-antibodies to Ct and Mg. 329 pregnant women and 135 men from the Finnish Family HPV study were analysed for serum IgG-antibodies of pGP3 for Ct and MgPa and rMgPa for Mg using multiplex serology. Seropersistence to both Ct and Mg was more common in women (30.4% and 13.3%) than in men (17.4% and 5.3%). The number of lifetime sexual partners above 10, practice of anal sex, and history of diagnosed Ct were associated with seropersistence to Ct in women, adjusted ORs 5.6 (95%CI 1.39-22.29), 15.3 (95%CI 1.18-197.12) and 18.0 (95%CI 5.59-57.92), respectively. The increasing number of partners before the age f 20 was the main risk factor for seropersistence among women with Mg, adjusted OR range from 5.0 to 12.3 (95%CI range 1.17-100.90) and in men only with 6 to 10 partners for Ct, adjusted OR 12.6 (95%CI 1.55-102.49). To conclude, persistent Ct antibodies were associated with various sexual activities, and Mg seropositivity was mainly associated with increased sexual activity in early 34 adulthood.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
Since its onset in 1998, the FFHPV study has been financially supported by the Academy of Finland
308 [SS, KL]; Päivikki and Sakari Sohlberg Foundation [SS, SG, KL]; Sigrid Jusélius Foundation [KL];
309 and the Finnish Medical Foundation [KL]. The authors declare no conflict of interest.


Last updated on 2025-12-09 at 15:24